US-based INOVA Diagnostics has launched QUANTA Lite Calprotectin, a new US Food and Drug Administration (FDA) cleared assay to aid diagnosis of inflammatory bowel disease (IBD).

The new assay can also help differentiate IBD from irritable bowel syndrome (IBS) in conjunction with other laboratory and clinical findings.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The new QUANTA Lite Calprotectin is a quantitative enzyme linked immunosorbent assay (ELISA) that detects calprotectin levels.

The company said accurate detection of calprotectin levels in stool can provide critical information to physicians determining the suitable care of patients suffering from gastrointestinal disorders.

Launch of this new assay further expands the INOVA Diagnostics portfolio in the area of autoimmune gastrointestinal disorders.

See Also:

INOVA Diagnostics vice president of Research and Development Michael Mahler said the compay is happy to launch this high performing assay to meet the increasing demand from laboratories worldwide.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

"Gastrointestinal pain is a common reason for seeking medical attention. Inaccurate diagnosis at the screening level can contribute to unnecessary procedures and increased healthcare costs," Mahler said.

"The QUANTA Lite Calprotectin assay can improve patient care while potentially reducing overall costs."

The company manufactures IVD systems and reagents for autoimmune disease that are used in clinical laboratories and hospitals across the world.

INOVA Diagnostics CEO Roger Inglès said that the benefits of fecal calprotectin testing are being recognized by healthcare systems around the world as evidenced by the recent recommendation from the National Institute for Health and Care Excellence (NICE) in the UK.

"As a worldwide leader in the autoimmunity in vitro diagnostics (IVD) market, INOVA Diagnostics is perfectly positioned to quickly increase awareness and adoption of this important new test across the globe," Inglès said.